Douglas L. Boggs - Concepedia

Author

Douglas L. Boggs

University of Maryland, Baltimore

Also Known As

D. L. Boggs, Douglas Boggs, Douglas L Boggs, Douglas L. Boggs, Douglas Lee Boggs

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

University of Maryland, Baltimore VA Connecticut Healthcare System National Institute on Drug Abuse National Institutes of Health VA Capitol Health Care Network

About

Douglas L. Boggs is an author at University of Maryland, Baltimore specializing in psychiatry, medicine, and schizophrenia.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	796
2	Health Sciences	5	5	352
3	Social Sciences	5	5	407
4	Public Health	1	1	37
5	Behavioral Sciences	1	1	37

Douglas L. Boggs

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial Douglas L. Boggs, Toral Surti, Aarti Gupta, Psychopharmacology Cannabis UsePsychopathologyPsychiatryPsychotic DisorderAddiction	2018	224
Cigarette Smoking and Mortality Risk in People With Schizophrenia Deanna L. Kelly, Robert P. McMahon, Heidi J. Wehring, Schizophrenia Bulletin	2009	156
Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers Kenneth H. Levin, Marc L. Copersino, Stephen J. Heishman, Drug and Alcohol Dependence Cannabis UseSubstance AbuseSubstance UseHealth SciencesPsychiatry	2010	147
Diagnostic criteria for cannabis withdrawal syndrome David A. Gorelick, Kenneth H. Levin, Marc L. Copersino, Drug and Alcohol Dependence Cannabis UseSubstance AbuseSubstance UseHealth SciencesPsychiatry	2011	116
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements Robert W. Buchanan, Julie Kreyenbuhl, Deanna L. Kelly, FOCUS The Journal of Lifelong Learning in Psychiatry Psychiatric EvaluationPsychotropic MedicationPsychopharmacologyExtensive Literature ReviewPharmacotherapy	2012	83
Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia Deanna L. Kelly, David A. Gorelick, Robert R. Conley, Journal of Clinical Psychopharmacology Overweight PeoplePsychiatric SymptomsPsychotropic MedicationPsychopharmacologySubstance Use Disorders	2010	58
Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial Douglas L. Boggs, Deanna L. Kelly, Robert P. McMahon, Schizophrenia Research PsychiatryPsychotic DisorderPsychotropic MedicationPsychopharmacologySchizophrenia	2011	52
A Randomized Double-Blind Trial of Atomoxetine for Cognitive Impairments in 32 People With Schizophrenia Deanna L. Kelly, Robert W. Buchanan, Douglas L. Boggs, The Journal of Clinical Psychiatry	2009	46
Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the “self-medication” hypothesis in schizophrenia Douglas L. Boggs, Toral Surti, Irina Esterlis, Schizophrenia Research Tobacco ControlSubstance AbuseBehavioral SciencesPsychopathologyPsychiatry	2017	37
A Survey of Prescribers' Attitudes, Knowledge, Comfort, and Fear of Consequences Related to an Opioid Overdose Education and Naloxone Distribution Program Alyssa M. Peckham, Maria E. Niculete, Howard R. Steinberg, Journal of Public Health Management and Practice	2017	37

Page 1